Category: ‘Clinical Trials and Studies’
Posted on November 7th, 2007
New experimental therapies are being — or soon may be — tested in clinical trials that could open the doors to a “golden era” for research to improve the treatments of people with spinal cord injuries, brain injuries, stroke, and other severe movement disorders, scientists say.
Posted on September 21st, 2007
According to the Spinal Cord Injury Information Network, there are about 11,000 new spinal cord injuries each year. Car accidents have been responsible for nearly 50 percent of spinal cord injuries since 2000, and falls have been the second most common cause of spinal cord injuries. Currently, about 253,000 Americans are living with a spinal cord injury.
Dr. Michael Fehlings from Toronto Western Hospital is studying a new drug to treat spinal cord injuries soon after they happen. The drug, called Cethrin, is applied during surgery to the injury site in a fibrin glue type of material. Cethrin is a recombinant protein that is made through artificial DNA technology. The protein inhibits Rho, a key pathway that triggers cell death and increases damage after a spinal cord injury.
Posted on August 10th, 2007
There’s been lots of confusion and some mischaracterizations about when the first embryonic stem cell clinical trial might take place and what it might treat. Spinal cord injury has been a leading candidate. Hans Keirstead, a scientist at the University of California at Irvine has been at the center of the discussions. His work, which has helped rats with severed spinal cords “walk” again, is funded by Geron, a biotech company in Northern California. Geron executives have adjusted their timeline for trials several times, which is perhaps understandable but has led to some of the confusion.
Posted on July 22nd, 2007
Bob Konieczko became partially paralyzed after falling off a roof. For the past three years, he’s been mostly confined to wheel chair but today he’s learning to walk again.
Posted on June 28th, 2007
Patients Experienced Increased Mobility After Treatment; Preliminary Results Involving 25 Patients Presented at International Society for Cellular Therapy’s Annual Meeting in Sydney
PrimeCell™ Therapeutics LLC announced that it provided research support and pre-clinical studies for a clinical trial to assess the safety, feasibility and efficacy of implanting autologous bone marrow stem cells into spinal cord injury (SCI) patients.